PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T‑SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti-CD40 agonist. IV dosing of...

Full "IntellAsia: Resources" article